Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

o the submission, review, potential approval of the NDA, development and commercialization of pharmaceutical products. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

[i] A. Grothey, et al. Results of a randomized Phase 3 trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients with mCRC who have progressed after standard therapies [January 17, 2012 ASCO-GI Presscast Presentation]. 2012 Gastrointestinal Cancers Symposium; January 19-21, 2012. San Francisco, CA.

[ii] American Cancer Society. Colorectal Cancer Guide. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003096-pdf.pdf. Accessed on October 14, 2011.

[iii] American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Available at: http://www.cancer.org/acs/groups/co
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015  Eli Lilly and ... AZN ) today announced that they have entered into ... preliminary efficacy of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, ... VEGF Receptor 2 antiangiogenic cancer medicine. The planned study ... with advanced solid tumors. The Phase I ...
(Date:5/29/2015)... , May 29, 2015 Educating ... of the Association for the Advancement of Wound ... With support from AAWC,s corporate partners, the ... Portal on the AAWC website at ... wound care pathway with links to various CME/CEU ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA ... financial results for the second quarter and three and six ... expressed in Canadian dollars and in accordance with International Financial ... ESSA recorded a net loss of $5.9 million ($0.35 ... 2015 (Q2-2015), compared to a net loss of $0.4 million ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14The Association for the Advancement of Wound Care Educates the Public 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... Presented at the 132nd Annual Meeting of the American Neurological ... Association in ... presented results from two,Phase III pivotal trials and one open-label ... restless legs,syndrome (RLS). These rotigotine data showed significant drops in ...
... Boehringer Ingelheim,Pharmaceuticals, Inc. today announced that ... full (traditional) approval of Aptivus(R),(tipranavir) capsules. The ... 2005; accelerated approval is a regulatory process ... or life-threatening illnesses. The full,approval of APTIVUS ...
Cached Medicine Technology:Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 2Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 3Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 4Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 2Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 3Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 4Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 6Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 7Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 8
(Date:5/29/2015)... 29, 2015 World Patent Marketing, a ... that it has signed a 10 year licensing agreement ... aims to let people learn about any topic and ... , "This is an exciting day for World Patent ... J. Cooper, CEO and Creative Director of World Patent ...
(Date:5/29/2015)... 29, 2015 Mediaplanet has joined forces ... protection”. Skin Health is a cross-platform campaign with ... markets of New York, Los Angeles, and Chicago, the ... Its digital counterpart will reach a national audience through ... more the Skin Health campaign and Colorescience, click ...
(Date:5/29/2015)... Dallas, TX (PRWEB) May 29, 2015 ... H1 2015” provides comprehensive information on the therapeutic ... different types of muscles in the body, leading ... strengthens R&D pipelines by identifying new targets and ... report on H1 2015 pipeline review of Axillary ...
(Date:5/29/2015)... Designed with the versatile athlete in mind, ... all new, exclusive line of supplementation called The 24/7 ... and greatest, high impact, result driven ingredients that have ... 24/7 Series can be used by anyone from bodybuilders ... fitness enthusiasts. There are no stimulant based ingredients that ...
(Date:5/29/2015)... 2015 The annual aesthetic meeting, put on ... held in Montreal from May 14-19th. This global event ... from around the world; dedicating itself exclusively to cosmetic medicine. ... renowned plastic surgeons to attend this year’s meeting. , ... Dr. Vitenas was given the honor of sitting at the ...
Breaking Medicine News(10 mins):Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3
... Corporation,(Nasdaq: DRRX ) announced today that James ... at the SIGnificant Investment Options,in Healthcare conference hosted ... at 2:45 p.m. EST. The conference is being ... York City., (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO ), ...
... but significant association , , FRIDAY, Feb. 28 (HealthDay News) ... and taking vitamin E may even heighten the risk, ... supplement-taking habits and lung cancer incidence of almost 78,000 ... period. , "Our study of supplemental multivitamins, vitamin C, ...
... Pitching ... Legend Tommy John, SARASOTA, Fla. ... and retail company focused on providing,hearing aids with state-of-the-art fidelity, price ... Square Mall,(Sarasota) and Gulf View Mall (Port Richey)., Years ago, ...
... Feb. 29 Landauer, Inc. (NYSE:,LDR) announced today that ... of $0.50 per share for the second quarter of ... 2008, to shareholders of record,on March 14, 2008., ... analytical services to determine,occupational and environmental radiation exposure. For ...
... Calif., Feb. 29 Genoptix, Inc.,(Nasdaq: GXDX ), ... stock being offered by certain existing stockholders to,the public ... will not,receive any proceeds from the sale. The offer ... offering is being made through an underwriting syndicate led ...
... Feb. 29 /Xinhua-PRNewswire-FirstCall/ -- Qiao Xing,Mobile Communication Co., Ltd. ... one of China,s leading domestic manufacturers of mobile,handsets through ... launch of its new C7000A cardiograph mobile handset., ... Cardiograph function -- Users will be able to perform ...
Cached Medicine News:Health News:Vitamin E Supplements May Raise Lung Cancer Risk 2Health News:Vitamin E Supplements May Raise Lung Cancer Risk 3Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 2Health News:Zounds! - Sarasota and Port Richey 'Hear' New Retail Concept Coming 3Health News:Genoptix Announces Pricing of Secondary Public Offering 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 2Health News:Qiao Xing Mobile's CECT Subsidiary Releases Newest Handset Model; C7000A Offers Cardiograph, 120 Days Ultra-Long Standby and 3.0'' LCD Screen 3
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... Seven digital models cover the range from 2ul ... fluently. Volume lock design prevents inadvertent volume ... horizontal grip. Whole pipette is autoclavable at ... is all polypropylene. Suitable for one-handed operation. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: